Cargando…

Prostate cancer, insulin, and androgen deprivation therapy

Detalles Bibliográficos
Autores principales:	Stattin, P, Kaaks, R
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2003
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394411/ https://www.ncbi.nlm.nih.gov/pubmed/14583790 http://dx.doi.org/10.1038/sj.bjc.6601351

Ejemplares similares

Reply: Prostate cancer, insulin and androgen deprivation therapy
por: Lehrer, S
Publicado: (2003)

Androgen deprivation therapy in high risk prostate cancer
por: Van Dams, Ritchell, et al.
Publicado: (2019)

Androgen deprivation and SARS-CoV-2 in men with prostate cancer
por: Koskinen, M., et al.
Publicado: (2020)

Androgen deprivation therapy for prostate cancer and risk of dementia
por: Robinson, David, et al.
Publicado: (2019)

On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2
por: Caffo, O., et al.
Publicado: (2020)

Androgen-deprivation therapy and SARS-CoV-2 in men with prostate cancer: findings from the University of California Health System registry
por: Kwon, D.H., et al.
Publicado: (2021)

Androgen deprivation therapy in unlikely to be effective for treatment of COVID-19
por: O'Callaghan, M.E., et al.
Publicado: (2020)

Risk of esophageal and gastric adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer
por: Shore, Richard, et al.
Publicado: (2021)

Worsening of the low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio in patients with prostate cancer after androgen deprivation therapy
por: Oka, Ryo, et al.
Publicado: (2018)

Initial 3-month dynamics of dehydroepiandrosterone sulfate can predict responsiveness to primary androgen deprivation therapy in patients with metastatic prostate cancer
por: Yano, Akihiro, et al.
Publicado: (2019)

Androgen deprivation therapy and excess mortality in men with prostate cancer during the initial phase of the COVID-19 pandemic
por: Gedeborg, Rolf, et al.
Publicado: (2021)

Risk of colorectal adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer; a nationwide cohort study
por: Shore, Richard, et al.
Publicado: (2023)

Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer
por: Crawley, Danielle, et al.
Publicado: (2016)

Androgen deprivation therapy and excess mortality during the COVID-19 pandemic
por: Stattin, P., et al.
Publicado: (2021)

Does androgen deprivation therapy protect against severe complications from COVID-19?
por: Patel, V.G., et al.
Publicado: (2020)

Susceptibility to SARS‐Cov‐2 infection and risk for severe COVID‐19 in patients with prostate cancer on androgen deprivation therapy
por: Gedeborg, Rolf, et al.
Publicado: (2022)

Cardiovascular Risks of Androgen Deprivation Therapy for Prostate Cancer
por: Corona, Giovanni, et al.
Publicado: (2021)

Androgen-deprivation therapy and SARS-Cov-2 infection: the potential double-face role of testosterone
por: Salciccia, Stefano, et al.
Publicado: (2020)

Androgen deprivation and cognition in prostate cancer
por: Salminen, E, et al.
Publicado: (2003)

Androgen deprivation therapy as backbone therapy in the management of prostate cancer
por: Merseburger, Axel S, et al.
Publicado: (2016)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
por: Fujimoto, Naohiro, et al.
Publicado: (2011)

Racial Differences in Chronic Stress/Allostatic Load Variation Due to Androgen Deprivation Therapy in Prostate Cancer
por: Stabellini, Nickolas, et al.
Publicado: (2022)

Metabolomic effects of androgen deprivation therapy treatment for prostate cancer
por: Chi, Jen‐Tsan, et al.
Publicado: (2020)

An Update on the Changing Indications for Androgen Deprivation Therapy for Prostate Cancer
por: Myklak, Kristene, et al.
Publicado: (2011)

Androgen deprivation therapy for prostate cancer and the risk of hematologic disorders
por: Liu, Jui-Ming, et al.
Publicado: (2020)

Relugolix – The novel oral androgen deprivation therapy for prostate cancer
por: Jena, Rahul
Publicado: (2020)

Androgen deprivation therapy may constitute a more effective COVID-19 prophylactic than therapeutic strategy
por: Bennani, N.N., et al.
Publicado: (2020)

Adjuvant androgen deprivation therapy for prostate cancer treated with radiation therapy
por: Siddiqui, Zaid A., et al.
Publicado: (2018)

Impact of Androgen Deprivation on Oxidative Stress and Antioxidant Status in Nigerian Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy
por: Bassey, Iya Eze, et al.
Publicado: (2020)

Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?
por: Amit, Uri, et al.
Publicado: (2019)

Weight Loss for Obese Prostate Cancer Patients on Androgen Deprivation Therapy
por: WILSON, REBEKAH L., et al.
Publicado: (2021)

Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer
por: Røe, Kathrine, et al.
Publicado: (2012)

Influence of Timing Between Androgen Deprivation Therapy and External Beam Radiation Therapy in Patients With Localized, High-Risk Prostate Cancer
por: McCall, Neal S., et al.
Publicado: (2021)

Cardiovascular Toxicities of Androgen Deprivation Therapy
por: Challa, Azariyas A., et al.
Publicado: (2021)

Cardiovascular Toxicity of Androgen Deprivation Therapy
por: Boland, Julia, et al.
Publicado: (2021)

Androgen deprivation therapy for prostate cancer: indications, contraindications and possible consequences
por: Karl, Alexander, et al.
Publicado: (2009)

Androgen-deprivation therapy-induced aggressive prostate cancer with neuroendocrine differentiation
por: Lipianskaya, Julia, et al.
Publicado: (2014)

Adverse Effects of Androgen Deprivation Therapy for Prostate Cancer: Prevention and Management
por: Sountoulides, Petros, et al.
Publicado: (2013)

Effect of androgen deprivation therapy on cardiovascular risk factors in prostate cancer
por: Roayaei, Mahnaz, et al.
Publicado: (2013)

Emerging potential of parenteral estrogen as androgen deprivation therapy for prostate cancer
por: Ali Shah, Syed Imran
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_43esj44l92gs01l4beqbb0gcbo